What's New At Isto.

We’re proud to announce the next installment of our Regenerative Medicine Educational Series. Our semi-annual peer-to-peer events explore physician-focused topics regarding the advancements in biologics and autologous therapy in medicine.

Isto Biologics’ Medical Education team recently supported a biologics Hospital-Based Observation Preceptorship led by Dr. Edgardo Rodriguez, DPM.

Isto Holdings, the parent company of St. Louis-based Isto Biologics has acquired Progenicare, a national medical sales and service company.

Isto Biologics’ Medical Education team recently supported a cadaver lab led by Dr. Blake Johnson, Medical Director at CDI – Twin Cities MN.

Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis with $1.5 billion of assets under management, announced today that it has acquired the commercial operations of ISTO Technologies (ISTO) headquartered in St. Louis, MO.

ISTO Technologies, Inc., a privately-held orthobiologic regenerative medicine company, announces the publication of positive clinical results reported for InQu® Bone Graft Extender & Substitute in a comparative study of two bone graft materials in posterolateral lumbar fusion.